Moreover, recent studies on individuals who were carriers of AD mutations showed that blood NfL levels were already increased more than a decade before the estimated age of onset of clinical manifestations and the NfL peak rate of increase is observed near to the onset of symptoms [25–27]. This evidence concerns the gene NEFL and Alzheimer disease.